Nurix Therapeutics NRIX 深 滬
等待開盤 11-05 09:30:00 美东时间
15.95
-9.870
-38.23%
華盛通- 最 高17.28
- 今 開17.16
- 成交量 1955.90万股
- 最 低 14.78
- 昨 收 25.82
- 總市值 17.43亿
- 52周最高 28.23
- 市盈率 靜 --
- 換手率 17.90%
- 52周最低 12.43
- 委 比 -2.73%
- 總股本 1.09亿
- 歷史最高 52.38
- 量 比 7.31
- 振 幅 9.68%
- 歷史最低 4.22
- 每 手 1
- 風險率 4.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多赛诺菲(SNY.US)叫停STAT6项目，Nurix(NRIX.US)盘前跌超30%！里程碑款与分成一并落空
Nurix Therapeutics(NRIX.US)在宣布其合作伙伴赛诺菲(SNY.US)决定停止一项实验性炎症疾病疗法的研究后，于周三盘前延续了此前的盘后跌...
11-04 21:28
Sanofi Discontinues Nurix Therapeutics STAT6 Degrader Program
The latest update is out from Nurix Therapeutics ( ($NRIX) ). On November 3, 20...
11-04 05:57
Nurix Therapeutics shares are trading lower after Sanofi notified the company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272.
Nurix Therapeutics shares are trading lower after Sanofi notified the company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272.
11-04 05:14
Nurix Therapeutics Announces That Sanofi Notified Co. Of Its Decision To Discontinue The Phase 1 First-In-Human Clinical Trial Of SAR448272, And To Terminate The SAR448272 Program
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to termi...
11-04 05:10
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
Nurix Therapeutics announced that Sanofi has discontinued the Phase 1 clinical trial of SAR448272, an oral STAT6 degrader, and terminated the program. As a result, Nurix will not receive future milestone payments or royalties related to SAR448272. However, the company remains eligible for payments from other licensed programs under the collaboration. Nurix has a strong cash runway of $1.1 billion, sufficient to fund operations into 2029. The comp...
11-03 21:01
SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised the price target for Strategy Inc (NASDAQ:MSTR) from $186 to $208. Cantor Fitzgerald ...
10-16 20:25
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.
10-13 18:24
CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly earnings of $4.73 per share which beat the analyst consensus estimate of $3.98 by 18.84 percent. This is a 559.22 percent increase over losses of $(1.03) per share from the same period last year. The company reported quarterly sales of $673.064 mil...
10-13 04:09
